Pumosetrag

N/A

Report date: 2022/11/25 16:34:12
NME

Base Information

Drug NamePumosetrag
Drug Alias NamePumosetragum盐酸普莫曲格盐酸普莫司曲Pumosetrag Hydrochloride普莫司曲盐酸盐 +[8] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionSerotonin 3 (5-HT3) receptor agonists
TargetsSerotonin 3 (5-HT3) receptor
Therapy Area/IndicationsIrritable Bowel SyndromeGastroesophageal Reflux
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCanadaUnited States
CombinationsNo
Global Highest StatusPending (Phase 3 Clinical)
Highest Status in ChinaN/A
Originator CompaniesMitsubishi Tanabe Pharma Corp
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesEdusa Pharmaceuticals IncDynogen Pharmaceuticals Inc
Active IndicationsN/A
Inactive IndicationsIrritable Bowel SyndromeGastroesophageal Reflux

Other Information

ATC CodeN/A
Related LinksN/A